Researchers from McMaster University and the Firestone Institute for Respiratory Health at St. Joseph’s Healthcare Hamilton, together with colleagues at other partnering institutions, have developed a new method to treat severe asthma.
In a study of over 200 participants with severe asthma, the new treatment was shown to have improved asthma symptoms and lung function, while reducing the need for corticosteroids by up to 70%.
According to Statistics Canada, eight per cent of Canadians aged 12 or older – approximately 2.4 million people – have been diagnosed with asthma. Of that, approximately 25% are considered to be severe cases of asthma.
Current treatments for severe asthma often include high doses of corticosteroids, such as prednisone, to control exacerbations. Reducing the need for corticosteroids with alternative treatments is preferable, since these medications are associated with serious side effects from prolonged use – including multi-organ toxicities and immunosuppression.
Parameswaran Nair, professor of medicine at McMaster and staff respirologist at St. Joseph’s Healthcare Hamilton, along with a team of researchers found that an antibody called dupilumab is effective in treating severe asthma in place of high doses of prednisone.
The results were published in the New England Journal of Medicine, one of the world’s most influential medical publications.
Researchers sought participants who had been using oral corticosteroids (prednisone) to treat severe asthma for at least six months prior to the study. In addition to their standard regimen of corticosteroids, patients received either dupilumab or a placebo during the 24 week trial. The corticosteroid dose was gradually reduced during weeks four to 20, and maintained at a low level for the final four weeks.
“The ability of dupilumab to increase lung function as markedly as it did in this study, even in the face of [corticosteroid] withdrawal, indicates that it appears to be inhibiting key drivers of lung inflammation,” the researchers noted.
Dupilumab works to treat asthma by blocking two specific proteins (called interleukin-4 and interleukin-13) that are associated with inflammation of the airways.
This technique was based on Nair’s previous research, (published in the New England Journal of Medicine in 2009 and in 2017). Those studies found that blocking another protein, interleukin-5, allowed patients with high eosinophil levels in their blood and airways to reduce their corticosteroid dose. Eosinophils are a type of white blood cell involved with the production of interleukins. High eosinophil levels are directly linked to an increased risk of severe asthma.
Unlike the previous studies, dupilumab was shown to be effective regardless of patients’ eosinophil levels. Despite the reduced prednisone dose, patients in this study not only experienced a decrease in asthma exacerbations, but their lung function also improved significantly.
“Ultimately, our goal is to find new treatment pathways that allow us to circumvent the use of corticosteroids,” said Nair.
“Since dupilumab showed a significant improvement on asthma control regardless of eosinophil levels, we may be able to use this treatment for a wider range of patients than we previously thought possible. This might be due to the broad effects on inflammation in asthma of the two proteins that we were able to block with dupilumab. The treatment was not associated with any serious side effects.”
The Latest on: Asthma
via Google News
The Latest on: Asthma
- A young mother died after asthma attack in rural MS. Why Mike Espy is sharing her storyon August 11, 2020 at 8:54 am
An asthma attack as a child nearly killed Mike Espy. Now, it shapes how he views Medicaid expansion in Mississippi.
- Woman, 34, died after fumes from mixing cleaning products caused fatal asthma attack in bathroomon August 11, 2020 at 7:41 am
A WOMAN died when she mixed two cleaning products together while cleaning the bathroom. Celia Seymour, also known as Leah, collapsed and struggled to breathe after telling her pal she was popping ...
- COPD and Asthma Devices Market Size to Grow $51.62 Billion, By 2027 at 4.3% CAGRon August 11, 2020 at 6:19 am
The COPD and asthma devices market size was estimated at $36.45 billion in 2019, and is anticipated to hit $51.62 billion by 2027, registering a CAGR of 4.3% from 2020 to 2027. Day-to-day exposure to ...
- AstraZeneca Partners with Actor and Author Tony Hale to Build Awareness of Eosinophilic Asthma and How Not All Asthma is the Sameon August 11, 2020 at 4:30 am
AstraZeneca is partnering with Tony Hale, two-time Emmy-winning actor and author, to share his lifelong journey as an asthma sufferer, in an effort to help others understand the importance of learning ...
- Your breathing problems may actually be caused by your stomach, not asthmaon August 11, 2020 at 12:35 am
Senior health correspondent Monica Robins reports on a common misdiagnosis and a new approach to clearing the air.
- Millions at risk of asthma attacks – which can be deadly – from triple weather threat, doc warnson August 11, 2020 at 12:35 am
MILLIONS of people across the UK are at risk of asthma attacks as the country battles a triple weather threat, experts have warned. Brits have basked in warm, sunny weather for the past week but ...
- What you need to know about students with asthma and COVID-19on August 10, 2020 at 12:53 pm
Here are 5 actions schools can take to help keep students with asthma safe and comfortable, including how to address instances of a student who experiences breathing difficulties while in school.
- Study: Thunderstorms Can Trigger Asthma Attacks That Need Hospitalizationon August 10, 2020 at 9:43 am
The calm before the storm isn't really so calm, at least not for anyone with asthma or other severe breathing disorders, new research shows.
- Thunderstorm Asthma Symptoms Peak Days Before A Storm Arriveson August 10, 2020 at 8:58 am
For some people, it’s the calm before the storm that causes them distress during rough weather seasons. It’s long been recognized that sudden changes in we ...
via Bing News